

**FOR IMMEDIATE RELEASE**

**Investors Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
**240-631-3280**  
[BurrowsR@ebsi.com](mailto:BurrowsR@ebsi.com)

**Media Contact:**

Tracey Schmitt  
Vice President, Global Public Affairs  
and Corporate Responsibility  
**240-631-3200**  
[SchmittT@ebsi.com](mailto:SchmittT@ebsi.com)

**EMERGENT BIOSOLUTIONS TO PARTICIPATE IN MARCH 2015 INVESTOR CONFERENCES**

**Gaithersburg, MD, February 20, 2015**—Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the following investor conferences in March 2015:

- **Cowen and Company 35<sup>th</sup> Annual Health Care Conference**  
**Boston**  
**March 2, 2015**  
**Presentation: 2:10PM Eastern**
- **Credit Suisse Under Followed Opportunities Conference**  
**Boston**  
**March 10, 2015**
- **MaidStone Life Sciences LLC 5<sup>th</sup> Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference**  
**New York**  
**March 26, 2015**

For the Cowen and Company conference, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com) under "[Investors](#)."

**About Emergent BioSolutions Inc.**

Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

Follow us on twitter: [@emergentbiosolu](https://twitter.com/emergentbiosolu).

###